CDSAF yields 5.53% · JNJ yields 2.14%● Live data
📍 JNJ pulled ahead of the other in Year 8
Combined, CDSAF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CDSAF + JNJ for your $10,000?
Cydsa, S.A.B. de C.V., together its subsidiaries, engages in the production and marketing of salt, chlorine, caustic soda, and refrigerant gases in Mexico, the United States, Canada, Central and South America, Asia, and Europe. It operates through Salt, Chlorine and Caustic Soda, Refrigerant Gases, and Energy Processing and Logistics segments. The company offers light salt, salt substitute, Kosher and halal grade salt, salt with chili and lime, and coarse sea salt for use in household and commercial human consumption, food industry, and industrial processes. It also provides chlorine, liquid and gas, chlorine in cylinders, sodium hypochlorite, caustic potash, synthetic hydrochloric acid, and muriatic acid, as well as liquid, solid, and rayon and membrane grade caustic soda for use in chemical and petrochemical industries, water treatment, oils, cellulose, papers, bottling, pesticides, bleaches, detergents and soaps, plastics, pigments, paints, and mining and extraction of metals. In addition, the company offers refrigerant, propellant, and blowing gases, as well as gases for fluoropolymers and anesthetic medical products for use in industrial, commercial and domestic refrigeration, home appliances, and pharmaceutical industries. Further, it is involved in the electricity and steam cogeneration business; and hydrocarbons processing and underground storage business, as well as provides liquid petroleum gas storage services. The company offers its products under the La Fina, Cisne, Marfil, Gallo, Palomitos, Bakará, Elefante, Klara, Carmen, Brisa de Occidente, Genetron, Aquion, and Eco Flush trademarks. Cydsa, S.A.B. de C.V. was founded in 1945 and is headquartered in Monterrey, Mexico.
Full CDSAF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.